The company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins ...

Teplizumab is thought to work by preventing the activation of T-cells that attack those cells. In a clinical trial, Tzield given once daily as an intravenous infusion for 14 days to patients with ...

赛诺菲中国8月28日宣布，中国国家药品监督管理局药品审评中心正式授予Tzield®（Teplizumab，替利珠单抗(拟)）优先审评资格，这预示着国内首个用于1 ...

Global Type 1 diabetes market is set to grow at a compound annual growth rate (CAGR) of 13.3 per cent from $2.2 billion in ...

The updated guidelines from the American Diabetes Association emphasize the use of antibody-based screening for type 1 ...